|
Apr 15
|
Transactions in Connection with Share Buy-back Program Genmab
|
|
Apr 3
|
Genmab Takes The Next Step In Its 'Evolution' With A $1.8 Billion Takeover
|
|
Apr 3
|
Stocks to Watch Wednesday: Disney, Intel, Tesla, Trump Media
|
|
Apr 3
|
Genmab buys ProfoundBio for $1.8B, adding to ADC dealmaking flurry
|
|
Apr 3
|
Genmab Strengthens Oncology Portfolio With $1.8 Bln Acquisition of ProfoundBio
|
|
Apr 3
|
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
|
|
Mar 25
|
Transactions in Connection with Share Buy-back Program
|
|
Mar 18
|
Completion of share buy-back program
|
|
Mar 17
|
30 Biggest Biotechnology Companies in the World
|
|
Mar 13
|
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
|
|
Mar 13
|
Passing of Genmab A/S’ Annual General Meeting
|
|
Feb 29
|
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
|
|
Feb 27
|
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
|
|
Feb 26
|
Transactions in connection with share buy-back program
|
|
Feb 23
|
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
|
|
Feb 15
|
Genmab A/S (NASDAQ:GMAB) Q4 2023 Earnings Call Transcript
|
|
Feb 15
|
Genmab: Growth Is Still a Better Choice
|
|
Feb 15
|
Notice to Convene the Annual General Meeting of Genmab A/S
|
|
Feb 14
|
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
|
|
Feb 14
|
Genmab Announces Initiation of Share Buy-Back Program
|